Serum chromogranin A correlation with tumor burden in metastatic small bowel carcinoid patients Abstract #29

Introduction: Patients with neuroendocrine tumors may have clinical courses that range from fairly indolent to more aggressive. Cross–sectional studies, nuclear imaging and biochemical markers are often used to monitor disease progression. Optimal surveillance tests and intervals have not been firmly established. Studies suggest that chromogranin A (CgA) may be a surrogate marker for tumor burden.
Aim(s): The aim of this study was to correlate serum CgA and serotonin levels with radiologically assessed hepatic tumor burden in patients with metastatic small bowel carcinoid.
Materials and methods: Clinical database query identified 57 patients with small bowel carcinoids with hepatic metastases. As part of clinical care, this cohort was evaluated with surveillance CT scans and serum biomarkers at the discretion of their physicians from 2001 to 2009. RECIST (Response Evaluation Criteria in Solid Tumors) guidelines with assessment of sum diameter of five largest hepatic metastases were applied by two independent observers to CT scans done within six months of serum biomarker collection. Sums were correlated with CgA and serotonin using Pearson correlation.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran

To read results and conclusion, please login ...

Further abstracts you may be interested in

#28 Prognostic Clinicopathologic Factors in Longitudinally Followed Patients with Metastatic Small Bowel Carcinoid
Introduction: Neuroendocrine tumors demonstrate heterogeneous behavior based upon site of origin and specific histology. Even after controlling for anatomic location, disease stage and histologic grade, registry studies show persistent diversity of outcome in patients with midgut carcinoid.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#112 Chromogranin A is a sensitive marker for detection of recurrence in neuroendocrine tumors
Introduction: The chromogranin family is a family of large acidic proteins which are expressed in neuroendocrine cells. There are several members in this family (Chromogranin A, B (CgA and CgB) and the secretogranins). Here, we show that CgA is an excellent marker to detect recurrence in neuroendocrine tumors.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Prof Eva Tiensuu Janson
#582 Comparison of biomarkers in predicting presence and severity of carcinoid heart disease in patients with metastatic mid-gut neuroendocrine tumours
Introduction: Carcinoid heart disease (CHD) is evaluated using echocardiography. The utility of plasma biomarkers for detecting the presence/severity of CHD is under-explored.
Conference:
Category: Clinical
Presenting Author: Dr Rebecca Dobson
#802 Metastatic Type 1 Gastric Carcinoid - A Real Threat or Just a Myth?
Introduction: Metastatic GCA1 are extremely rare and there is no data about their natural history, treatment and prognosis.
Conference: 11th Annual ENETS Conference (2014)
Category: ...none of the below
Presenting Author: Dr. Simona Glasberg
#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong